These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 14644)

  • 21. [Incorporation of adriamycin into cell nuclei and interaction between adriamycin and DNA (author's transl)].
    Negishi T; Takahira H
    Yakugaku Zasshi; 1973 Nov; 93(11):1498-508. PubMed ID: 4798536
    [No Abstract]   [Full Text] [Related]  

  • 22. In vitro and in vivo study of cross resistance between daunorubicin and daunorubicin-DNA complex in Ehrlich ascites tumor.
    Skovsgaard T
    Cancer Chemother Pharmacol; 1979; 2(1):43-7. PubMed ID: 498419
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cellular pharmacokinetics of aclacinomycin A in cultured L1210 cells. Comparison with daunorubicin and doxorubicin.
    Zenebergh A; Baurain R; Trouet A
    Cancer Chemother Pharmacol; 1982; 8(2):243-9. PubMed ID: 6955072
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic, toxicologic, and chemotherapeutic properties of detorubicin in mice: a comparative study with daunorubicin and adriamycin.
    Deprez-de Campeneere D; Baurain R; Trouet A
    Cancer Treat Rep; 1979 May; 63(5):861-7. PubMed ID: 455327
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The incorporation of heat-denatured DNA by cells of the Ehrlich-Lettré ascites carcinoma in vitro.
    Meizel S; Kay ER
    Biochim Biophys Acta; 1966 Jul; 123(1):34-8. PubMed ID: 6007168
    [No Abstract]   [Full Text] [Related]  

  • 26. Increased uptake of actinomycin D in Ehrlich ascites tumour cells induced by daunorubicin.
    Lund-Andersen C; Skovsgaard T; Nissen NI
    Cancer Chemother Pharmacol; 1983; 10(2):79-83. PubMed ID: 6831629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Uptake and retention of adriamycin and daunorubicin by sensitive and anthracycline-resistant sublines of P388 leukemia.
    Inaba M; Johnson RK
    Biochem Pharmacol; 1978; 27(17):2123-30. PubMed ID: 31880
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacological and therapeutic efficacy of rubidazone in mice. Comparison with daunomycin and adriamycin.
    Ohnuma T; Elias F; Holland JF; Henderson E
    Eur J Cancer (1965); 1979 Mar; 15(3):363-71. PubMed ID: 446517
    [No Abstract]   [Full Text] [Related]  

  • 29. Cellular pharmacology of detorubicin and doxorubicin in L1210 cells.
    Zenebergh A; Baurain R; Trouet A
    Eur J Cancer Clin Oncol; 1984 Jan; 20(1):115-21. PubMed ID: 6537910
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of CO, KCN and NaN3 on the nucleic acid content of Ehrlich ascites tumor cells.
    Jeney E; Medve F
    Biochem Pharmacol; 1967 Oct; 16(10):1899-902. PubMed ID: 6065955
    [No Abstract]   [Full Text] [Related]  

  • 31. Preferential binding of adriamycin and nogalamycin to DNase-I hypersensitive sites of Sarcoma-180 chromatin.
    Panda CK; Choudhury K; Neogy RK
    Chem Biol Interact; 1986 Jan; 57(1):65-72. PubMed ID: 3948285
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Subcellular localization of some anthracycline derivatives in Ehrlich ascites tumor cells.
    Londos-Gagliardi D; Capri M; Aubel-Sadron G; Maral R
    Biochem Biophys Res Commun; 1980 Nov; 97(2):397-406. PubMed ID: 7470104
    [No Abstract]   [Full Text] [Related]  

  • 34. Characterization of tumor cell resistance to 4'-deoxy-4'-iododoxorubicin developed in Ehrlich ascites cells in vivo.
    Friche E; Danks MK; Beck WT
    Cancer Res; 1992 Oct; 52(20):5701-6. PubMed ID: 1356619
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increase in the incorporation of 3H-thymidine triphosphate into the DNA of nuclei isolated from Ehrlich ascites-tumour cells irradiated in vivo.
    Matsudaira H; Furuno I
    Int J Radiat Biol Relat Stud Phys Chem Med; 1971; 19(4):393-7. PubMed ID: 5314116
    [No Abstract]   [Full Text] [Related]  

  • 36. Some determinants of the therapeutic efficacy of actinomycin D (NSC-3053), adriamycin (NSC-123127), and daunorubicin (NSC-83142).
    Schwartz HS
    Cancer Chemother Rep; 1974; 58(1):55-62. PubMed ID: 4521481
    [No Abstract]   [Full Text] [Related]  

  • 37. Uptake and subcellular localization of daunorubicin and adriamycin in cultured fibroblasts.
    Noel G; Peterson C; Trouet A; Tulkens P
    Eur J Cancer (1965); 1978 Apr; 14(4):363-8. PubMed ID: 648557
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of cytosine arabinoside triphosphate on deoxyribonucleic acid synthesis in permealysed cells from Ehrlich ascites tumour. Studies of phosphorylated drub metabolites on quasi-normal deoxyribonucleic acid replication.
    Burgoyne LA
    Biochem Pharmacol; 1974 May; 23(11):1619-27. PubMed ID: 4847536
    [No Abstract]   [Full Text] [Related]  

  • 39. DNA synthesis in nuclei isolated from Ehrlich ascites tumor cells.
    Teng C; Bloch DP; Roychoudhury R
    Biochim Biophys Acta; 1970 Nov; 224(1):232-45. PubMed ID: 5490255
    [No Abstract]   [Full Text] [Related]  

  • 40. Rubidazone vs adriamycin: an evaluation of their differential toxicity in the spleen colony assay system.
    Alberts DS; Van Daalen Wetters T
    Br J Cancer; 1976 Jul; 34(1):64-8. PubMed ID: 952715
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.